Method and composition for inducing human pluripotent stem cells
US-2017159022-A1 · Jun 8, 2017 · US
Method and composition for inducing human pluripotent stem cells
US10190097B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10190097-B2 |
| Application number | US-201615383752-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 19, 2016 |
| Priority date | Oct 21, 2011 |
| Publication date | Jan 29, 2019 |
| Grant date | Jan 29, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides a method of forming a fibromodulin (FMOD) reprogrammed (FReP) cell. The method comprises steps of treating a human cell with a cell culture medium comprising fibromodulin (FMOD) for a period ranging from a day to a month, and changing the cell culture medium regularly until a FMOD reprogrammed (FreP) cell forms; wherein the FreP cell expresses NANOG and does not form teratoma, and wherein the human cell is a fibroblastic cell.
First claim
Opening claim text (preview).
We claim: 1. A method of pluripotency reprogramming, comprising: treating a human cell with a cell culture medium comprising fibromodulin (FMOD) for a period ranging from a day to a month, and changing the cell culture medium regularly until a FMOD reprogrammed (FreP) cell forms; wherein the FreP cell expresses NANOG and does not form teratoma, and wherein the human cell is a fibroblastic cell. 2. The method according to claim 1 , wherein the FMOD has a concentration from about 200 nM to about 800 nM. 3. The method according to claim 1 , wherein the human cell is a BJ fibroblast or primary adult normal human dermal fibroblast (NHDF).
Assignees
Inventors
Classifications
Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00) · CPC title
Transforming growth factor beta (TGF-β) · CPC title
- C12N5/0696Primary
Artificially induced pluripotent stem cells, e.g. iPS · CPC title
Fibroblasts · CPC title
Proteins not provided for elsewhere · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10190097B2 cover?
- The present invention provides a method of forming a fibromodulin (FMOD) reprogrammed (FReP) cell. The method comprises steps of treating a human cell with a cell culture medium comprising fibromodulin (FMOD) for a period ranging from a day to a month, and changing the cell culture medium regularly until a FMOD reprogrammed (FreP) cell forms; wherein the FreP cell expresses NANOG and does not f…
- Who is the assignee on this patent?
- Univ California
- What technology area does this patent fall under?
- Primary CPC classification C12N5/0696. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).